The crossroad between autoimmune disorder, tissue remodeling and cancer of the thyroid: The long pentraxin 3 (PTX3)

Chiari, Damiano; Pirali, Barbara; Perano, Vittoria; Leone, Roberto; Mantovani, Alberto; Bottazzi, Barbara

doi:10.3389/fendo.2023.1146017

Cited by 3 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it has been shown that PTX3 may play a role as an extrinsic tumor-suppressor gene by controlling complement-dependent and macrophage-associated tumor-promoting inflammation [47]. Its expression has been found, among others, in lung cancer, glioma, ovarian cancer, myxoid liposarcoma, prostate carcinoma, esophageal squamous cell carcinoma, and pancreatic cancer [48]. Interestingly, PTX3 has been also shown as a biomarker (prognostic indicator of short-term mortality) of clinical PASC (post-acute sequelae of SARS-CoV-2), also known as post-COVID syndrome [49,50].…”

Section: Pentraxin Familymentioning

confidence: 99%

The Role of Pentraxin 3 in Gastrointestinal Cancers

Zajkowska,

Mroczko

2023

Cancers

View full text Add to dashboard Cite

Gastrointestinal cancers have become a huge problem worldwide as the number of new cases continues to increase. Due to the growing need to explore new biomarkers and therapeutic targets for the detection and treatment of cancerous lesions, we sought to elucidate the role of Pentraxin-3 in the progression of cancerous lesions, as it is involved in the process of angiogenesis and inflammation. Statistically significant changes in the concentration of this parameter have emerged in many gastrointestinal cancer patients. Moreover, it is related to the advancement of cancer, as well as processes leading to the development of those changes. In the case of studies concerning tissue material, both increased and decreased tissue expression of the tested parameter were observed and were dependent on the type of cancer. In the case of cell lines, both human and animal, a significant increase in Pentraxin 3 gene expression was observed, which confirmed the changes observed at the protein level. In conclusion, it can be assumed that PTX3, both at the level of gene expression and protein concentrations, is highly useful in the detection of gastrointestinal cancers, and its use as a biomarker and/or therapeutic target may be useful in the future.

show abstract

Section: Pentraxin Familymentioning

confidence: 99%

The Role of Pentraxin 3 in Gastrointestinal Cancers

Zajkowska,

Mroczko

2023

Cancers

View full text Add to dashboard Cite

show abstract

Thyroid cytology in pediatric patients: a single-center study from 2015 to 2023—is there a necessity for distinct treatment approaches for patients with and without autoimmune thyroiditis?

Kujdowicz,

Januś,

Radliński

et al. 2024

Virchows Arch

View full text Add to dashboard Cite

The management of thyroid nodules is guided by the cytological classification provided by The Bethesda System for Reporting Thyroid Cytology. Notably, the biology of thyroid tumors in pediatric patients differs from that in adults, and there is limited research focused on pediatric cases. This study aimed to assess the effectiveness of the Bethesda system in pediatric patients treated at the largest tertiary pediatric thyroid center in Poland between 2015 and 2023. A retrospective analysis was conducted on 566 patients with thyroid nodules, of whom 555 underwent fine-needle aspiration biopsy (FNAB). A total of 217 patients underwent thyroid surgery. Of these, 206 had previously undergone FNAB with cytological evaluation at our center, while 11 patients underwent thyroid surgery due to a RET mutation or the need for an extended procedure. The initial FNAB results showed distribution across Bethesda categories as follows: 7.6% for category I, 54.6% for category II, 20.9% for category III, 4.1% for category IV, 7.6% for category V, and 5.6% for category VI. Among patients who underwent surgery, the distribution of Bethesda categories I through VI was 2.9%, 25.2%, 29.1%, 8.3%, 19.4%, and 15%, respectively. The risk of malignancy (ROM) from the initial FNAB was estimated at 33.3%, 11.5%, 22.2%, 4.8%, 84.4%, and 96.8% for Bethesda categories I through VI, respectively. In patients with autoimmune thyroiditis (AIT), the ROM was higher than in non-AIT patients for Bethesda categories I through IV, while it was lower in category VI. The sensitivity for detecting non-benign neoplasms across Bethesda categories III through VI was approximately 86% in both AIT and non-AIT patients. However, for papillary thyroid carcinoma, sensitivity in Bethesda categories V and VI was 86% in non-AIT patients but decreased to 61.5% in AIT patients. These findings emphasize the importance of considering surgical intervention in pediatric patients with Bethesda III-VI cytology, particularly in those with AIT.

show abstract